India, Oct. 9 -- Fagron NV (FAGR.BR), a pharmaceutical company, on Thursday released financial results for the third quarter, noting a significant surge in revenue as certain segments outperformed previous year sales.
The company focuses on pharmaceutical compounding to offer personalized medicines to hospitals, pharmacies, and clinics in more than 40 countries worldwide.
Q3 Financial Results:
For the three months ending September 30, 2026, Fagron recorded a revenue of €281.26 million, reflecting a 23.2% increase from €228.22 million earned in the same period of 2025.
Revenue in the European Mediterranean Economic Area (EMEA) increased over 31% to €0.11 million, driven by sales in the Compounding Services. However, sal...